Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,780 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M. González-Martín A, et al. Among authors: lopez r, lopez vivanco g. Curr Cancer Drug Targets. 2016;16(5):415-28. doi: 10.2174/1568009615666150817121731. Curr Cancer Drug Targets. 2016. PMID: 26278712 Review.
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.
Feliu J, Safont MJ, Salud A, Losa F, García-Girón C, Bosch C, Escudero P, López R, Madroñal C, Bolaños M, Gil M, Llombart A, Castro-Carpeño J, González-Barón M. Feliu J, et al. Among authors: lopez r. Br J Cancer. 2010 May 11;102(10):1468-73. doi: 10.1038/sj.bjc.6605663. Epub 2010 Apr 27. Br J Cancer. 2010. PMID: 20424611 Free PMC article. Clinical Trial.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Baselga J, et al. Lancet. 2012 Feb 18;379(9816):633-40. doi: 10.1016/S0140-6736(11)61847-3. Epub 2012 Jan 17. Lancet. 2012. PMID: 22257673 Free PMC article. Clinical Trial.
Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.
Alba E, Ciruelos E, López R, López-Vega JM, Lluch A, Martín M, Muñoz M, Sánchez-Rovira P, Seguí MÁ, Liria MR, Pérez-Alcántara F. Alba E, et al. Among authors: lopez r, lopez vega jm. Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):381-91. doi: 10.1586/erp.13.18. Epub 2013 Mar 28. Expert Rev Pharmacoecon Outcomes Res. 2013. PMID: 23534988 Clinical Trial.
Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.
Carrato A, García P, López R, Macarulla T, Rivera F, Sastre J, Gostkorzewicz J, Benedit P, Pérez-Alcántara F. Carrato A, et al. Among authors: lopez r. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):579-89. doi: 10.1586/14737167.2015.1047349. Epub 2015 May 19. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25991037
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
Janni W, Alba E, Bachelot T, Diab S, Gil-Gil M, Beck TJ, Ryvo L, Lopez R, Tsai M, Esteva FJ, Auñón PZ, Kral Z, Ward P, Richards P, Pluard TJ, Sutradhar S, Miller M, Campone M. Janni W, et al. Among authors: lopez r. Breast Cancer Res Treat. 2018 Jun;169(3):469-479. doi: 10.1007/s10549-017-4658-x. Epub 2018 Feb 5. Breast Cancer Res Treat. 2018. PMID: 29404806 Clinical Trial.
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ. Cruz C, et al. Among authors: lopez r. J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21. J Clin Oncol. 2018. PMID: 30240327 Free PMC article. Clinical Trial.
Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval.
Ciruelos E, Alba E, López R, Lluch A, Martín M, Arroyo I, Navarro B, Carcedo D, Colomer R, Albanell J. Ciruelos E, et al. Among authors: lopez r. Oncotarget. 2019 Jul 2;10(42):4321-4332. doi: 10.18632/oncotarget.27039. eCollection 2019 Jul 2. Oncotarget. 2019. PMID: 31303965 Free PMC article.
Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer.
Ciruelos EM, Díaz MN, Isla MD, López R, Bernabé R, González E, Cirauqui B, Coves J, Morales S, Arcediano A, Barneto I, Cerezuela P, Illarramendi JJ, Morales C, Ponce S. Ciruelos EM, et al. Among authors: lopez r. Eur J Cancer Care (Engl). 2019 Nov;28(6):e13164. doi: 10.1111/ecc.13164. Epub 2019 Sep 30. Eur J Cancer Care (Engl). 2019. PMID: 31571304
3,780 results